Delcath Systems patented a method for selecting cytotoxic agents for organ-specific therapy. The method involves filtering blood to remove the agent before returning it to the mammal. The patent outlines a detailed process for screening, identifying, and optimizing chemotherapeutic agents and filtration media for efficient treatment. GlobalData’s report on Delcath Systems gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Delcath Systems Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Delcath Systems, Wearable breast pumps was a key innovation area identified from patents. Delcath Systems's grant share as of February 2024 was 93%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11867686B2) outlines a method for obtaining and optimizing a chemotherapeutic agent filtration media pair for the treatment of cancer in mammals. The method involves screening chemotherapeutic agents with cancer cell lines to determine their effectiveness, identifying an agent suitable for high-dose, short-term exposure, and developing a filtration media comprising activated carbon to efficiently remove the agent from the blood. By varying parameters of the activated carbon, such as density, pore volume, and surface area, the filtration media is optimized to achieve a filtration efficiency of at least 80%.

Furthermore, the patent details a process for further optimizing the filtration media by testing its efficiency in adsorbing the chemotherapeutic agent from blood. By infusing the agent in an extracorporeal circuit and measuring its concentration before and after filtration, the filtration efficiency is calculated. The method aims to achieve a filter efficiency of at least 90% by varying the parameters of the filtration media containing activated carbon. The patent specifies that the isolated organ treatment mentioned in the claims is percutaneous hepatic perfusion and that the method is intended for use in human patients, highlighting its potential application in clinical settings for cancer treatment.

To know more about GlobalData’s detailed insights on Delcath Systems, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies